The use of a compound of Formula (1): wherein for example: X and Y are independently selected from: oxygen, sulphur and (--CR.sup.aR.sup.b--).sub.n; wherein: n is an integer of from 1 to 4 and R.sup.a and R.sup.b are each independently selected from hydrogen, C.sub.1-6altkyl, C.sub.1-6alkoxy, halo, hydroxy, C.sub.1-6alkanoyloxy, C.sub.3-12cycloalkyl and optionally substituted phenyl or R.sup.a and R.sup.b together form a C.sub.5-12spirocycloalkyl or a carbonyl; R.sup.1 and R.sup.3 are independently selected from (a) optionally substituted phenyl or phenoxy; (b) optionally substituted naphth-1-yl or naphth-2-yl; (c) arylC.sub.1-6alkyl; (d) C.sub.1-20alkyl or C.sub.1-20alkenyl; and (e) adamantyl or a C.sub.3-12cycloalkyl R.sup.2 is hydrogen, a C.sub.1-8alkyl or benzyl; or pharmaceutically acceptable salt, pro-drug or solvate thereof as DGAT inhibitors and in the manufacture of a medicament for the treatment of type II diabetes and/or obesity.